comparemela.com
Home
Live Updates
Riccardo Lencioni - Breaking News
Pages:
2
3
4
5
6
7
8
Riccardo Lencioni News Today : Breaking News, Live Updates & Top Stories | Vimarsana
TACE Plus Durvalumab and Bevacizumab Could Alter SOC in Embolization-Eligible, Unresectable HCC
Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.
Riccardo lencioni
Department of surgery
Cancers symposium
Critical area pathology
Riccardo lencioni
Chemoembolization tace
Urvalumab imfinzi
Nd bevacizumab avastin
Hepatocellular carcinoma
Phase 3 emerald 1 trial nct03778957
Durvalumab Plus Bevacizumab Improves TACE Outcomes in HCC
A new study showed improved progression-free survival when systemic therapy is added to TACE for HCC. Overall survival outcomes are pending.
United states
New york
Josep llovet
Riccardo lencioni
University of pisa
American society of clinical oncology
American society
Clinical oncology
Mount sinai hospital
Hepatocellular carcinoma hcc liver cancer of the
Angiogenesis inhibitor
Humanized monoclonal antibody
Rastuzumab humanised monoclonal antibody
Biologic therapy
Vascular endothelial growth factor
Highlights from the Gastrointestinal and Genitourinary Cancer Conferences
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
United states
Riccardo lencioni
Michiels van
Drug administration
American society
Clinical oncology
Gastrointestinal cancers symposium
Genitourinary cancers
Gastrointestinal cancers
Der heijden
Neal shore
Gastric cancer
Prostate cancer
Kidney cancer
Bladder cancer
Asco gi24
Imfinzi, Avastin, TACE May Set a New Standard of Care in Liver Cancer
Adding Imfinzi and Avastin to transarterial chemoembolization led to a 23% reduction in the risk of progression or death in patients with liver cancer.
Imfinzi avastin
Riccardo lencioni
Department of surgery
Critical area pathology
Asco gastrointestinal cancers symposium
Liver cancer
New Standard for Unresectable Hepatocellular Carcinoma?
Adding durvalumab and bevacizumab to transarterial chemoembolization almost doubles PFS
Comunidad autonoma de cataluna
New york
United states
Josepm llovet
Charles bankhead
Riccardo lencioni
University of barcelona
University of pisa
Icahn school of medicine at mount sinai
Gastrointestinal cancers
Icahn school
Mount sinai
New york city
Medpage today
vimarsana © 2020. All Rights Reserved.